• Lucid Diagnostics secured a commercial coverage policy from Concert for its EsoGuard esophageal DNA test, effective July 2026.
• Concert cited published guidelines and peer-reviewed evidence, classifying EsoGuard as medically necessary for patients meeting ACG screening criteria.
• Multiple Concert client health plans have adopted the policy, expanding potential reimbursement access across those plans.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608050846PR_NEWS_USPR_____NY19812) on August 05, 2026, and is solely responsible for the information contained therein.